Zim Laboratories cash flow

Latest FY26

Cash from operations: ₹49.5cr+20.4% on FY25
Capital spending: ₹44.4cr+8.8% on FY25
Free cash flow: ₹5.1cr+1,342.3% on FY25
Cash from financing: ₹28.2cr−₹9.1 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023

Adjustments to reconcile profit — non-cash items
	—	20.0	20.1	16.0	17.5
	—	13.2	11.4	6.9	5.6
	—	−0.3	−0.1	−0.0	−0.1
	—	−0.0	0.0	0.0	0.0
	—	1.1	1.4	0.0	0.0
	—	−2.8	−0.3	−1.1	−1.0
	—	−0.2	−0.7	−0.2	0.8
	—	−1.8	0.6	0.5	−0.6
Changes in working capital
	—	−7.3	−5.2	−27.6	21.6
	—	1.1	−8.0	−4.7	−5.4
	—	5.8	−0.7	−1.3	8.2
	—	−0.0	−0.1	−0.7	0.4
	—	0.2	−0.1	−0.4	−0.5
	—	3.4	7.1	4.1	−22.8
	—	−0.3	2.7	−1.5	2.7
	—	13.0	−6.1	5.3	−17.0
Cash from operating activities
	5.1	8.2	18.0	23.6	35.4
	—	45.1	22.1	−4.8	9.3
	—	53.3	40.1	18.9	44.7
	—	3.7	−1.1	2.6	7.1
	—	49.5	41.2	16.3	37.5
Cash from investing activities
	—	44.4	40.8	73.9	36.7
	—	5.6	0.7	0.5	0.0
	—	0.0	0.0	0.0	0.0
	—	0.2	0.0	0.0	0.1
	—	−17.8	0.1	0.3	0.4
	—	−56.3	−39.9	−73.0	−36.2
Cash from financing activities
	—	35.0	0.0	0.0	0.0
	—	0.1	0.0	0.0	0.0
	—	24.8	24.6	28.1	18.4
	—	14.7	17.8	−19.2	9.9
	—	3.9	3.6	1.7	1.9
	—	12.9	12.3	7.5	5.5
	—	−0.2	0.0	21.4	−0.5
	—	28.2	−9.1	59.5	0.5
	—	21.4	−7.9	2.8	1.9
	—	1.8	0.2	0.4	1.1
	—	23.2	−7.7	3.2	3.0
	—	—	—	9.6	6.4
Reference items
	28.2	30.0	43.7	41.3	52.0
	7.1%	8.0%	11.5%	11.3%	13.0%
	5.1	5.1	0.4	−57.6	0.9
	—	3.1	−6.1	−18.4	—
	₹0.96	₹0.96	₹0.07	−₹10.77	₹0.16
	146.82×	—	—	—	—
	—	8.48×	3.38×	0.94×	1.54×
	—	3.7	−1.1	2.6	7.1
	—	12.9	12.3	7.5	5.5

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ZIMLAB₹141.26

Zim Laboratories Limited

· Pharma & Health

₹ CrorePeersANUHPHR VALIANTLAB AHCL ALBERTDAVD WANBURY HALEOSLABS BAJAJHCARE THEMISMEDMcap ₹756 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	17.5	16.0	20.1	20.0	—
+ Finance Costs	5.6	6.9	11.4	13.2	—
+ Interest Income	-0.1	-0.0	-0.1	-0.3	—
+ Dividend Income	0.0	0.0	0.0	-0.0	—
+ Share-based Payments	0.0	0.0	1.4	1.1	—
+ Unrealised FX (Gain) / Loss	-1.0	-1.1	-0.3	-2.8	—
+ Other Non-cash Items	0.8	-0.2	-0.7	-0.2	—
+ Other Reconciling Items	-0.6	0.5	0.6	-1.8	—
Changes in Working Capital
+ Inventories	21.6	-27.6	-5.2	-7.3	—
+ Trade Receivables — Current	-5.4	-4.7	-8.0	1.1	—
+ Other Financial Assets — Current	8.2	-1.3	-0.7	5.8	—
+ Other Financial Assets — Non-current	0.4	-0.7	-0.1	-0.0	—
+ Other Non-current Assets	-0.5	-0.4	-0.1	0.2	—
+ Trade Payables — Current	-22.8	4.1	7.1	3.4	—
+ Other Financial Liabilities — Current	2.7	-1.5	2.7	-0.3	—
+ Other Non-current Liabilities	-17.0	5.3	-6.1	13.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	35.4	23.6	18.0	8.2	5.1
+ Total Adjustments (incl. Working Capital)	9.3	-4.8	22.1	45.1	—
Cash from Operations (pre-tax)	44.7	18.9	40.1	53.3	—
+ Income Taxes Paid	7.1	2.6	-1.1	3.7	—
Cash from Operating Activities	37.5	16.3	41.2	49.5	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	36.7	73.9	40.8	44.4	—
+ Disp of Fixed Assets	0.0	0.5	0.7	5.6	—
+ Dividends Received — Investing	0.0	0.0	0.0	0.0	—
+ Interest Received — Investing	0.1	0.0	0.0	0.2	—
+ Other Inflows / (Outflows) — Investing	0.4	0.3	0.1	-17.8	—
Cash from Investing Activities	-36.2	-73.0	-39.9	-56.3	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	0.0	0.0	35.0	—
+ Proceeds from Exercise of Stock Options	0.0	0.0	0.0	0.1	—
+ Proceeds from Borrowings	18.4	28.1	24.6	24.8	—
+ Repayment of Borrowings	9.9	-19.2	17.8	14.7	—
+ Payment of Lease Liabilities	1.9	1.7	3.6	3.9	—
+ Interest Paid	5.5	7.5	12.3	12.9	—
+ Other Inflows / (Outflows) — Financing	-0.5	21.4	0.0	-0.2	—
Cash from Financing Activities	0.5	59.5	-9.1	28.2	—
Net Changes in Cash (pre-FX)	1.9	2.8	-7.9	21.4	—
+ Effect of FX Rate Changes on Cash	1.1	0.4	0.2	1.8	—
Net Changes in Cash	3.0	3.2	-7.7	23.2	—
Closing Cash	6.4	9.6	—	—	—
Reference Items
EBITDA	52.0	41.3	43.7	30.0	28.2
EBITDA Margin %	13.04	11.25	11.54	8.02	7.11
Free Cash Flow (CFO − Capex)	0.9	-57.6	0.4	5.1	5.1
Free Cash Flow to Equity	—	-18.4	-6.1	3.1	—
Free Cash Flow per Basic Share	0.16	-10.77	0.07	0.96	0.96
Price to Free Cash Flow	—	—	—	—	146.82
Cash Flow to Net Income	1.54	0.94	3.38	8.48	—
Cash Paid for Taxes	7.1	2.6	-1.1	3.7	—
Cash Paid for Interest	5.5	7.5	12.3	12.9	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.